Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Altimmune, Inc. (NASDAQ:ALT) has been given a consensus rating of “Moderate Buy” by the nine brokerages that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $20.83.

A number of equities analysts have commented on ALT shares. William Blair started coverage on shares of Altimmune in a report on Friday. They issued a “market perform” rating for the company. Stifel Nicolaus started coverage on shares of Altimmune in a report on Wednesday, January 8th. They issued a “buy” rating and a $18.00 target price for the company. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Altimmune in a research note on Wednesday, February 5th. Finally, UBS Group started coverage on Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target on the stock.

Altimmune Stock Performance

Shares of Altimmune stock opened at $6.65 on Wednesday. The company has a market capitalization of $472.98 million, a PE ratio of -4.29 and a beta of 0.19. The company has a 50-day simple moving average of $6.85 and a two-hundred day simple moving average of $7.20. Altimmune has a one year low of $5.28 and a one year high of $14.05.

Altimmune (NASDAQ:ALT) last announced its earnings results on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.01. The business had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. On average, equities analysts predict that Altimmune will post -1.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Altimmune

Large investors have recently bought and sold shares of the company. Larson Financial Group LLC acquired a new position in Altimmune in the 3rd quarter valued at $31,000. SBI Securities Co. Ltd. purchased a new stake in shares of Altimmune in the fourth quarter valued at approximately $45,000. Virtus ETF Advisers LLC purchased a new position in Altimmune in the fourth quarter worth approximately $60,000. Cullen Frost Bankers Inc. purchased a new position in Altimmune in the fourth quarter worth approximately $72,000. Finally, Sunbelt Securities Inc. lifted its stake in Altimmune by 356.8% during the fourth quarter. Sunbelt Securities Inc. now owns 10,844 shares of the company’s stock worth $79,000 after purchasing an additional 8,470 shares in the last quarter. Hedge funds and other institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.